Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New device aims to prevent leaks after colon cancer surgery

NCT ID NCT06402188

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 11, 2026 · Updated 3 times

Summary

This study tests a device called ColoSeal ICD that is placed inside the colon after surgery to divert stool away from the surgical connection. The goal is to see if it is safe and feasible in 90 adults with rectal or rectosigmoid cancer. The device stays in place for about 10 days and is then removed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ColoSeal ICD Device (a temporary tube placed in the colon to divert stool away from a surgical connection)
What this could lead to
If it works, this device could reduce the risk of serious leaks after colon surgery, potentially making recovery safer and faster.
What could go wrong
This is an early feasibility study with only 90 participants, so results may not apply to everyone. The device could cause infection, migration, or other complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject is 18-65 years of age at screening, or subject is 66-70 years of age at screening with up to one cardiovascular, metabolic or pulmonary comorbidity for which medication is prescribed. * Subject is diagnosed with rectosigmoid or rectal cancer * Subject is scheduled for elective resection, either open, laparoscopic or robotic with mesorectal excision (either abdominal or transanal approach) which will require the creation of an anastomosis and protective ostomy (anastomosis maximally 15 cm from the anal verge). * The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB). * Subject must be willing and able to comply with study follow-up requirements. Exclusion Criteria: * Subject with a life expectancy \< 1 year * Subjects with ASA classification \> 3 * Albumin \< 30 g/liter * Subject has local or systemic infection at the time of intervention. * Major surgical or interventional procedures within 30 days prior to this study or planned major surgical or interventional procedures within 1 month of entry into this study * Patient has received systemic chemotherapy or radiation to the pelvis within 30 days prior to the planned procedure * Subject has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis, diverticulitis, or extensively spread inflammatory bowel disease * Subject has an anatomic abnormality (e.g., polyp, diverticula, vascular malformation) or bowel damage at or within 5 cm of the target device anchor site that could interfere with safe device function * Subjects has a diagnosis of coagulopathy, thrombocytopenia, immune suppression * BMI ≥ 40 * Subject is scheduled for a concurrent major surgical procedure during the surgery (e.g., liver resection) * Subject has been taking regular systemic/ steroid medication in the last 3 months * Subjects is taking antimetabolites or antiplatelet agents (with the exception of aspirin) * Subject has undergone a prior pelvic anastomosis * Subject requires an end-to-end anastomosis smaller than 31 mm in diameter * Inadequate bowel preparation prior to the procedure * Anastomotic leak detected during intraoperative leak testing * Known allergy to any component of the device * Known allergy to iodine or iodine-based contrast unless subject can be adequately premedicated prior to leak test * Subject has unresolved alcohol abuse or illegal drug use * Any condition or abnormality which in the opinion of the investigator may jeopardize the subject's safe participation or the quality of the data * Subject is pregnant or planning to become pregnant. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure * Subject is unable or unwilling to provide informed consent * Subject is currently participating in an investigational drug or another device study that clinically interferes with the current study endpoints

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Israeli-Georgian Medical Research Clinic Healthycore

    Tbilisi, 0112, Georgia

  • National Cancer Institute

    Tashkent, Uzbekistan

  • National Center of Oncology after V.A. Fanarjian

    Yerevan, Armenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.